These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 28107583)

  • 21. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C.
    Roth D; Bloom RD; Molnar MZ; Reese PP; Sawinski D; Sise ME; Terrault NA
    Am J Kidney Dis; 2020 May; 75(5):665-683. PubMed ID: 32279907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus infection in end-stage renal disease and kidney transplantation.
    Burra P; Rodríguez-Castro KI; Marchini F; Bonfante L; Furian L; Ferrarese A; Zanetto A; Germani G; Russo FP; Senzolo M
    Transpl Int; 2014 Sep; 27(9):877-91. PubMed ID: 24853721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Hepatitis C Virus Infection in Dialysis Patients.
    Kikuchi K
    Contrib Nephrol; 2018; 196():119-122. PubMed ID: 30041215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.
    Muñoz-Gómez R; Rincón D; Ahumada A; Hernández E; Devesa MJ; Izquierdo S; Ortiz M; Hernández-Albujar A; Fernández-Rodríguez C; Calvo M; González R; Lozano M; Castellano G; Fernández-Vázquez I
    J Viral Hepat; 2017 Jun; 24(6):464-471. PubMed ID: 27976490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals.
    Ko SY; Choe WH
    Clin Mol Hepatol; 2018 Dec; 24(4):351-357. PubMed ID: 29544240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment and management options for the hepatitis C virus infected kidney transplant candidate.
    Dejman A; Ladino MA; Roth D
    Hemodial Int; 2018 Apr; 22 Suppl 1():S36-S44. PubMed ID: 29694726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.
    D'Ambrosio R; Pasulo L; Giorgini A; Spinetti A; Messina E; Fanetti I; Puoti M; Aghemo A; Viganò P; Vinci M; Menzaghi B; Lombardi A; Pan A; Pigozzi MG; Grossi P; Lazzaroni S; Spinelli O; Invernizzi P; Maggiolo F; Terreni N; Monforte AD; Poggio PD; Taddei MT; Colombo S; Pozzoni P; Molteni C; Brocchieri A; Bhoori S; Buscarini E; Centenaro R; Mendeni M; Colombo AE; Di Marco M; Dionigi E; Bella D; Borghi M; Zuin M; Zaltron S; Noventa F; Annalisa S; Lampertico P; Fagiuoli S
    Dig Liver Dis; 2020 Feb; 52(2):190-198. PubMed ID: 31813755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.
    Li T; Qu Y; Guo Y; Wang Y; Wang L
    Liver Int; 2017 Jul; 37(7):974-981. PubMed ID: 27943605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy.
    Martínez-Campreciós J; Riveiro-Barciela M; Muñoz-Gómez R; Londoño MC; Roget M; Serra MÁ; Escudero-García D; Purchades L; Rodríguez M; Losa-García JE; Gutiérrez ML; Carmona I; García-Samaniego J; Morano L; Martín-Granizo I; Montero-Alonso M; Prieto M; Delgado M; Ramos N; Azancot MA; Rodríguez-Frías F; Buti M
    Gastroenterol Hepatol; 2023 Oct; 46(8):594-602. PubMed ID: 36584754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age and gender differences in the relationship between hepatitis C infection and all stages of Chronic kidney disease.
    Li WC; Lee YY; Chen IC; Wang SH; Hsiao CT; Loke SS
    J Viral Hepat; 2014 Oct; 21(10):706-15. PubMed ID: 24304473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C in Chronic Kidney Disease: An Overview of the KDIGO Guideline.
    Awan AA; Jadoul M; Martin P
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2158-2167. PubMed ID: 31376491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy.
    Mazzaro C; Quartuccio L; Adinolfi LE; Roccatello D; Pozzato G; Nevola R; Tonizzo M; Gitto S; Andreone P; Gattei V
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: Results from ERCHIVES.
    Butt AA; Ren Y; Puenpatom A; Arduino JM; Kumar R; Abou-Samra AB
    Liver Int; 2018 Aug; 38(8):1411-1417. PubMed ID: 29271562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).
    Minutolo R; Aghemo A; Chirianni A; Fabrizi F; Gesualdo L; Giannini EG; Maggi P; Montinaro V; Paoletti E; Persico M; Perticone F; Petta S; Puoti M; Raimondo G; Rendina M; Zignego AL;
    Dig Liver Dis; 2018 Nov; 50(11):1133-1152. PubMed ID: 30266305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Novel antiviral agents for the treatment of HCV among renal transplant recipients].
    Fabrizi F; Donato FM; Messa P
    G Ital Nefrol; 2017 Aug; 34(4):35-50. PubMed ID: 28762681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and drug interactions of medications used to treat hepatitis C virus infection in the setting of chronic kidney disease and kidney transplantation.
    Ortiz GA; Trivedi HD; Nader C
    Hemodial Int; 2018 Apr; 22 Suppl 1():S22-S35. PubMed ID: 29694720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HCV and the kidney.
    Corouge M; Vallet-Pichard A; Pol S
    Liver Int; 2016 Jan; 36 Suppl 1():28-33. PubMed ID: 26725894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease.
    Bruchfeld A; Lindahl K
    Semin Dial; 2019 Mar; 32(2):135-140. PubMed ID: 30475421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HCV Antiviral Therapy in Liver Transplant Candidates and Recipients With Renal Insufficiency.
    Verna EC; Brown RS
    Transplantation; 2017 May; 101(5):924-932. PubMed ID: 28212220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
    Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O
    Scand J Gastroenterol; 2017 May; 52(5):585-588. PubMed ID: 28270038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.